Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06401343
PHASE4

Use of SGLT2i in noHCM With HFpEF

Sponsor: China National Center for Cardiovascular Diseases

View on ClinicalTrials.gov

Summary

This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive HCM patients with HFpEF.

Official title: Sodium-dependent Glucose Transporters 2 Inhibitor in Nonobstructive Hypertrophic Cardiomyoapthy Patients With Heart Failure With Preserved Ejection Fraction: a Prospective, Multi-center,Open-lable,Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

94

Start Date

2022-08-01

Completion Date

2025-08-01

Last Updated

2024-05-06

Healthy Volunteers

No

Interventions

DRUG

Empagliflozin 10 MG

Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.

Locations (1)

Fuwai Hospital, National Centre for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China